# Open Label, Dose Escalation Phase I Study of AZD2281

> **NCT00572364** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 18 (estimated)

## Conditions studied

- Advanced Solid Malignancies

## Interventions

- **DRUG:** KU-0059436 (AZD2281)(PARP inhibitor)

## Key facts

- **NCT ID:** NCT00572364
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11
- **Primary completion:** 2009-03
- **Final completion:** 2009-06
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2009-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00572364

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00572364, "Open Label, Dose Escalation Phase I Study of AZD2281". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00572364. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*